Department of Urology and Andrology, Faculty of Medicine, Benha University Hospital, Benha, Egypt.
Department of Urology and Andrology, Faculty of Medicine, Benha University Hospital, Benha, Egypt.
Urology. 2023 May;175:114-119. doi: 10.1016/j.urology.2023.01.028. Epub 2023 Feb 1.
To evaluate the safety and efficacy of platelet rich plasma (PRP) injections as a therapeutic modality for mild to moderate erectile dysfunction.
A placebo-controlled study of 100 cases with mild to moderate erectile dysfunction. Participants were allocated to 2 groups; the PRP group received 3 injections (3 mL each corpus) and the interval between injections was 15 days, while the Placebo (Saline) group received 6 mL saline injected intracavernous. Postinjection follow-up lasted 6 months.
Compared to the placebo group, the PRP group demonstrated a significant improvement at the 1 and 3 months follow-up that slightly dropped at the 6 months follow-up (P <.001). The improvement was evident in the duplex parameters, International Index of Erectile Function Erectile Function (IIEF-EF), SEP Q2, and 3. At 1-month post-treatment follow-up (76%) patients in the PRP group had an improved IIEF-EF as they attained a minimal clinically important difference compared to (18%) in the saline group. At the 3-months post-treatment follow-up, (72%) patients achieved a minimal clinically important difference in the PRP group vs (16%) in saline group then dropped to (70%) in the PRP group vs (16%) in saline group at the 6-months post-treatment follow up. Patients' overall and intercourse satisfaction levels were higher in the PRP group than the placebo group as demonstrated with the higher IIEF score Q6, 7, 8, and IIEF score Q13, 14 respectively with the maximum improvement reported at the 3 months follow-up. No reports of plaque formation, subcutaneous bruising, or any other major side effects among participants.
PRP is a safe and promising method for the improvement of mild to moderate erectile dysfunction.
评估富血小板血浆(PRP)注射作为治疗轻度至中度勃起功能障碍的一种治疗方法的安全性和有效性。
对 100 例轻度至中度勃起功能障碍患者进行安慰剂对照研究。将参与者分为 2 组;PRP 组接受 3 次注射(每个 corpora 3 毫升),注射间隔为 15 天,而安慰剂(盐水)组接受 6 毫升盐水腔内注射。注射后随访持续 6 个月。
与安慰剂组相比,PRP 组在 1 个月和 3 个月随访时表现出显著改善,在 6 个月随访时略有下降(P <.001)。PRP 组在双功能参数、国际勃起功能指数勃起功能(IIEF-EF)、SEP Q2 和 3 方面有明显改善。在治疗后 1 个月的随访中(76%),PRP 组患者的 IIEF-EF 有所改善,与盐水组(18%)相比达到了最小临床重要差异。在治疗后 3 个月的随访中,PRP 组有(72%)患者达到了最小临床重要差异,而盐水组则为(16%),随后在治疗后 6 个月的随访中,PRP 组下降至(70%),而盐水组则为(16%)。与安慰剂组相比,PRP 组患者的总体和性交满意度更高,IIEF 评分 Q6、7、8 和 IIEF 评分 Q13、14 均有所提高,最大改善报告在 3 个月的随访中。没有参与者报告斑块形成、皮下瘀伤或任何其他严重副作用。
PRP 是一种安全且有前途的治疗轻度至中度勃起功能障碍的方法。